ENTRY       D06649                      Drug
NAME        Tadocizumab (USAN)
FORMULA     C2107H3252N562O673S12
EXACT_MASS  47579.417
MOL_WEIGHT  47608.5074
SEQUENCE    (A chain)
            QVQLVQSGAE VKKPGSSVKV SCKASGYAFT NYLIEWVRQA PGQGLEWIGV IYPGSGGTNY
            NEKFKGRVTL TVDESTNTAY MELSSLRSED TAVYFCARRD GNYGWFAYWG QGTLVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTH
            (B chain)
            DIQMTQTPST LSASVGDRVT ISCRASQDIN NYLNWYQQKP GKAPKLLIYY TSTLHSGVPS
            RFSGSGSGTD YTLTISSLQP DDFATYFCQQ GNTLPWTFGQ GTKVEVKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: A22-A96, A146-A202, A222-B214, B23-B88, B134-B194)
  TYPE      Peptide
EFFICACY    Platelet aggregation inhibitor, Anti-glycoprotein IIb/IIIa antibody
  TYPE      Monoclonal antibody, bispecific antibody
COMMENT     Treatment of patients undergoing percutaneous coronary interventions
TARGET      ITGA2B/ITGB3 [HSA:3674 3690] [KO:K06476 K06493]
  PATHWAY   hsa04611(3674+3690)  Platelet activation
            hsa04640(3674+3690)  Hematopoietic cell lineage
BRITE       Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: other families
               Integrins
                ITGA2B/ITGB3
                 D06649  Tadocizumab (USAN)
DBLINKS     CAS: 339086-80-5
            PubChem: 47208300
///
